Researchers at South Korea's KAIST have developed a nanoparticle-based therapy that reprograms immune cells already inside tumors into cancer-fighting machines — no cell extraction required. The team, led by Professor Ji-Ho Park, delivered mRNA-loaded lipid nanoparticles directly into tumors, converting dormant macrophages into CAR-macrophages capable of recognizing and destroying cancer cells.

Solid tumors like gastric, lung, and liver cancers form dense structures that block most immune therapies. Traditional CAR-macrophage treatments require extracting patient blood cells, culturing them, and genetically modifying them — a costly and slow process. KAIST's approach bypasses all of that by targeting tumor-associated macrophages in situ with two components: CAR-encoding mRNA and a STING agonist that supercharges the immune response.

In melanoma animal models, the therapy significantly slowed tumor growth. More remarkably, the immune response spread systemically, suggesting potential against metastatic cancers. The enhanced CAR-macrophages not only killed cancer cells directly but also activated surrounding immune cells, creating a cascading anti-tumor effect. Results were published in ACS Nano.